Clinical trial · Observational
Watch-and-Wait After Immunochemotherapy in Locally Recurrent Nasopharyngeal Carcinoma
Watch-and-Wait Strategy in Patients With Objective Response After Immuno-chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma: A Prospective Multicenter Observational Study
NCT07088484CI-TRIAL-00092661not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to compare chemotherapy plus immunotherapy with immunochemotherapy combined subsequent locoregional radiotherapy in recurrent nasopharyngeal carcinoma (NPC), in order to confirm the value of immunotherapy and chemotherapy in recurrent NPC patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Recurrent Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ICI-chemotherapy and LIMT | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- ICI-chemotherapy cohort
- description
- All included patients will undergo protocolized ICI-chemotherapy for 4-6 cycles, following by LIMT.
- interventionNames
- Drug: ICI-chemotherapy and LIMT
Primary outcomes (1)
- measure
- 2-year progression-free survival
- timeFrame
- Counting from the start of the treatment for two years.
- description
- Defined as the time from the initiation of ICI-chemotherapy to disease progression or death for any reason, whichever occurred first.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ≥ 18 years, regardless of sex. 2. Treatment-naïve patients with newly diagnosed metastatic nasopharyngeal carcinoma (NPC). 3. Receiving immunotherapy. (or Treated with immunotherapy) 4. At least one measurable tumor lesion according to RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1. 5. Adequate organ function. 6. Signed and dated informed consent form indicating that the patient (or legally authorized representative) has been informed of all pertinent aspects of the study. 7. Patients willing and able to comply with scheduled visits and study procedures. Exclusion Criteria: 1. Patients with distant metastasis of nasopharyngeal carcinoma. 2. Patients who have not received immunotherapy or chemotherapy. (Alternatively: No prior immunotherapy or chemotherapy.) 3. History of another active malignancy within the past 5 years, except for malignancies with a negligible risk of metastasis or death (e.g., expected 5-year overall survival \>90%) or malignancies treated with curative intent and with no evidence of disease (e.g., adequately treated carcinoma in situ of the cervix, basal cell or squamous cell carcinoma of the skin, localized prostate cancer treated with curative intent, ductal carcinoma in situ of the breast treated surgically with curative intent). 4. Lack of capacity to provide informed consent.
References
Publications (0)
Data not yet available
No reference posted for this study.